DSS1 promoter hypomethylation and overexpression predict poor prognosis in melanoma and squamous cell carcinoma patients

详细信息    查看全文

• 作者：Mario Venza ; MD^a ; ¹ ; Maria Visalli ; PhD^b ; ¹ ; Teresa Catalano ; MD ; PhD^b ; Concetta Beninati ; PhD^c ; ^d ; Diana Teti ; MD^e ; Isabella Venza ; MD^b ; ^{isavenza@gmail.com}
• 关键词：DSS1 ; Hypomethylation ; Overexpression ; Melanoma ; Squamous cell carcinoma
• 刊名：Human Pathology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：60
• 期：Complete
• 页码：137-146
• 全文大小：1345 K
• 卷排序：60

文摘

Previous studies have found a link between high expression levels of the Deleted in Split hand/Split foot 1 (DSS1) gene and cancer progression. The aim of this study was to examine whether overexpression of DSS1 is a feature of melanoma and squamous cell carcinoma (SCC) and if any epigenetic modifications are involved. Evaluation of DSS1 expression profile indicated that the gene is overexpressed in 112 of 130 cutaneous melanomas (86.1%), 41 of 64 uveal melanomas (64.1%), 67 of 82 mucosal melanomas (81.7%), and 61 of 75 SCC samples (81.3%), relative to normal skin. An inverse correlation between DSS1 expression and methylation status of the promoter was found. In vitro studies showed that treatment of DSS1-methylated melanoma and SCC cells with the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine significantly increased DSS1 expression at mRNA and protein levels. Interestingly, a significant association between high DSS1 expression levels and some clinicopathological variables, such as metastasis, ulceration, and reduced overall/disease-free survival was observed. In summary, these data suggest that the extent of promoter methylation plays a role in modulating DSS1 gene expression and highlight that promoter hypomethylation is a frequent event in melanoma and SCC closely linked to poor prognosis.